Ramírez SMLP, Calva RRG, Rojas EV, Pérez CS

Language: Spanish
References: 26
Page: 74-80
PDF size: 153.31 Kb.

ABSTRACT

Acute diarrhea in children is a public health problem in our country. The cases persist despite vaccination against rotavirus and other strategies, such as the recommendation of breastfeeding, use of drinking water, drainage, and dietary hygiene measures. Strategies have not been sufficient and hospital emergency rooms continue to receive children with diarrhea and dehydration. The most involved germs are viruses, followed by bacteria. The use of antibiotics should be for patients with severe or immunosuppressed disease, in these patients the antimicrobial treatment is empirical and is modified according to the result of the stool culture, antimicrobial susceptibility and clinical course. The use of an antimicrobial should preferably be considered to act locally and not affect the intestinal microbiota. New vaccines are currently being evaluated to reduce the incidence, morbidity, and mortality of the pediatric population. In this communication, the knowledge and management of diarrhea at the outpatient level are updated.

REFERENCES

1. Ramírez Sandoval, M.L.P., Macías Parra, MN., RamosGarcía, J. y Palacios Ramírez, E.G., “Tratamiento de ladiarrea aguda en el paciente pediátrico”, Rev Enf InfeccPed, 2006, 78: 26-34.

2. Richardson-López, C., Bautista-Márquez, A., Sánchez-Uribe, E., y Esparza-Aguilar, M., “Impacto poblacionala 10 años de la vacunación contra rotavirus enMéxico”, Salud Publica Mex, 2020, 62 (1).

3. Coronell Rodríguez, W., Villanueva Acosta L. y GómezBarreto, D., “Gastroenteritis”. En Infectología clínica pediátrica,8ª ed., México, McGraw Hill, 2011, pp.165-188.

4. Organización Mundial de la Salud (oms), “Gastroenteritisinfecciosa 2017”. Disponible en: https://www.who.int/es/news-room/fact-sheets/detail/diarrhoeal-disease.

5. Flores, I.D., Niño-Serna, L.F. y Beltrán-Arroyave, C.P.,“Acute infectious diarrhea and gastroenteritis in children”,Curr Infect Dis Rep, 2020, 22: 4.

6. Secretaría de Salud, Dirección General de Epidemiología,"Veinte principales causas de enfermedad nacionalpor grupos de edad”, México, 2021.

7. Organización Mundial de la Salud (oms), “Enfermedadesdiarreicas”. Disponible en: who.int/es/news-room/factsheets/detail/diarrhoeal-diseases.

8. Secretaría de Salud, Dirección General de Epidemiología,“Manual de procedimientos estandarizados parala vigilancia epidemiológica de la enfermedad diarreicaaguda (eda), enero de 2022”. Disponible en: https://epidemiologia.salud.gob.mx/gobmx/salud/documentos/manuales/44_Manual_EDA_2022.pdf.

9. Calvo Romero, C., Marugan de Miguelsanz, J.M. yBartolomé Porro, J.M., Tratado de gastroenterología ynutrición pediatrica aplicada, Sociedad Española deGastroenterología, Hepatología y Nutrición Pediátrica(seghnp), 2010, pp. 93-101.

10. Vázquez Narváez, J.A., Ramírez Sandoval, M.L.P. y VarelaRamírez, M.A., “Gastroenteritis infecciosa”. EnProntuario de infectología, 7ª ed., México, UniversidadAutónoma de San Luis Potosí, 2021, pp. 383-390.

11. Patzi-Vargas, S. et al., “Diarrheagenic Escherichia colicarrying supplementary virulence genes are an importantcause of moderate to severe diarrheal disease inMexico”, plos Negl Trop Dis, 2015, 9 (3): e0003510.

12. Román Riechmann, E., Barrio Torres, J. y López Rodríguez,M.J., Protocolos diagnóstico-terapéuticos degastroenterología, hepatología y nutrición pediátrica,Sociedad Española de Gastroenterología, Hepatologíay Nutrición Pediátrica (seghnp)-Asociación Española dePediatría (aep), Madrid, 2010, pp. 11-20.

13. Velázquez F., R et al., “Rotavirus infection in infants asprotection against subsequent infections”, N Engl JMed, 1996, 335: 1022-1028.

14. D’Amico, F., Baumgart, C.C., Danese, S. y Peyrin-Biroulet,L., “Diarrhea during covid-19 infection: pathogenesis,epidemiology, prevention, and management”, ClinGastroenterol Hepatol, 2020, 18: 1663-1672.

15. Guarino, A., Ashkenazi, S., Gendrel, D., Lo Vecchio, A.,Shamir R. y Szajewska, H., “European Society for PediatricGastroenterology, Hepatology, and Nutrition/European Society for Pediatric Infectious Diseases Evidence-Based Guidelines for the Managament of AcuteGastroenteritis in Children in Europe: Update 2014”, JPediatr Gastroenterol Nutr, 2014, 59 (1): 132-152.

16. Arroyo Cruz, L.V. y Montes Gaona, V.G., Clínicas mexicanasde pediatría gastroenterología, 1ª ed., 2022, México,pydesa, pp. 95-112.

17. Radicioni, M., Koirala, R., Fiore, W., Leuratti, Ch., Guglielmetti,S. y Arioli, S., “Survival of L cassei DF (Lactobacilluspaacasei cncm i-1572) in the gastrointestinal tract ofhealthy paediatric population”, Eur J Nutr, 2019, 58 (8):3161-3170.

18. Arioli, S., Koirala, R., Taverniti, V., Fiore, W. y Guglielmetti,S., “Quantitative recovery of viable Lactobacillus paracaseicncm i-1572 (L. casei dg®) after gastrointestinal passagein healthy adults”, Front Microbiol, 2018, 9: 1720.

19. Balzaretti, S. et al., “A novel rhamnose-rich hetero-exopolysaccharide 1 isolated from Lactobacillus paracaseidg activates thp-1 human monocytic cells”, ApplEnviron Microbiol, 2017, 83 (3): e02702-16.

20. Ferrario, Ch. et al., “Modulation of faecal Clostridialesbacteria and butyrate by probiotic intervention with Lactobacillusparacasei dg varies among healthy adults”, JNutr, 2014, 144 (11): 1787-1796.

21. Cagan, E., Ceylan, S., Mengi, S., Hasret Cagan, H., “Evaluationof gelatin tannate against symptoms of acutediarrhea in pediatric patients”, Med Sci Monit, 2017, 23:2029-2034.

22. Carretero, E.J., Durban Reguera, F., López-Argueta Álvarez,S. y López Montes, J., “A comparative analysisof response to ors + gelatin tannate pediatric patientswith acute diarrhea”, Rev Esp Enferm Dig, 2009, 101 (1);41-48.

23. Gutiérrez Castrellon, P. et al., “Guía de práctica clínicaibero-latinoamericana sobre el manejo de la gastroenteritisaguda en menores de 5 años: enfoque, alcances ydiseño”, An Pediatr (Barcelona), 2014, 80 (Suppl 1): 1-4.

24. Karlowicz-Bodalska, K., Glowacka, K., Boszkiewica, K.,Stanislaw, H. y Wiela-Hojenska, A., “Safety oral, nifuroxazide:analysis of date from a spontaneous reportingsystem”, Acta Poliniae Pharmaceutica-Drug Research,2019, 4: 745-751.

25. Sesin M., O. y Segreda Sagot, L.R., “Nifuroxazida en eltratamiento de la diarrea aguda bacteriana en niños: 50casos”, Rev Med Costa Rica, 1987, 54 (499): 45-47.

26. Rahimic, J., Alibegovic, E., Kurtcehajic, A., Lekic, L., Alibegovic,D. y Dautovic, E., “Does nifuroxazide enhancethe effect of metronidazole oral administration in thetreatment Clostridium difficile infection?”, jpri, 2022, 34(51A): 17-24.